Assessment of the Adrenergic Effects of Orphenadrine in Rat Vas Deferens

@article{Pubill1999AssessmentOT,
  title={Assessment of the Adrenergic Effects of Orphenadrine in Rat Vas Deferens},
  author={David Pubill and A. M. Canudas and Merc{\'e} Pall{\`a}s and Francesc X Sureda and Elena Escubedo and Antoni Camins and Jorge Camarasa},
  journal={Journal of Pharmacy and Pharmacology},
  year={1999},
  volume={51}
}
The peripheral adrenergic effects of orphenadrine, an antiparkinsonian drug, have been evaluated in the rat vas deferens to investigate whether these properties are the same as those of other phencyclidine ligands. 
Comparison of the Analgesic Effects of a Fixed-Dose Combination of Orphenadrine and Diclofenac (Neodolpasse®) with its Single Active Ingredients Diclofenac and Orphenadrine
TLDR
The observed effect was mainly caused by central mechanisms and was found to be superior for the fixed-dose combination of orphenadrine and diclofenac compared with the individual ingredients, which can be explained by the different molecular mechanisms of action of each drug.
[New treatment options for piriformis syndrome].
TLDR
Modern approaches to the diagnosis and management of patients with piriformis syndrome are discussed, and new possibilities of treating this syndrome using a fixed combination of diclofenac and orphenadrine registered in the Russian Federation as a drug for intravenous infusion neodolpasse are discussed.
Pain: Physiologic background and therapeutic Consequences
TLDR
A better understanding of the mechanisms involved in perception and transmission of nociceptive inputs as well as peripheral and central downregulating feedback may help to create individualize analgesic treatment regimens for complicated pain syndromes.

References

SHOWING 1-10 OF 24 REFERENCES
Glutamate and kainate effects on the noradrenergic neurons innervating the rat vas deferens
TLDR
It is concluded that noradrenergic neurons of the vas deferens are under glutamatergic control and that this might be important in the motor control of the organ.
Inhibition of orphenadrine of 3H-dl-noradrenaline and 14C-tyramine uptake in atria.
MK-801 enhances noradrenergic neurotransmission in rat vas deferens.
Characterization of [3H]nisoxetine binding in rat vas deferens membranes: modulation by sigma and PCP ligands.
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
TLDR
The findings of the present study are not conclusive but show a clear need for further research in this field and the paucity of evidence for the effectiveness of anti-cholinergic drugs in both Parkinson's disease and in drug-induced Parkinsonism.
Are NMDA antagonistic properties relevant for antiparkinsonianlike activity in rats?—Case of amantadine and memantine
TLDR
It can be assumed that the doses of amantadine, memantine and MK-801 showing antiparkinsonian-like activity in animals result in plasma levels leading to NMDA antagonism, but in the haloperidol-induced catalepsy test the efficacy of amanadine was higher than memantine, while the opposite was true for rotation and reserpine-induced sedation indicating pharmacodynamic differences between both agents.
l-Glutamic acid, a neuromodulator of dopaminergic transmission in the rat corpus striatum
Role of the sigma receptor in the inhibition of [3H]-noradrenaline uptake in brain synaptosomes and adrenal chromaffin cells.
TLDR
The results indicate that the central and peripheral inhibitory effects of PCP and sigma-receptor ligands on [ 3H]-NA uptake involves a receptor (sigma 1-like) which is distinct from that (PCP2) recognized for the inhibition of [3H]-dopamine uptake by PCP.
Role of the σ receptor in the inhibition of [3H]‐noradrenaline uptake in brain synaptosomes and adrenal chromaffin cells
TLDR
The results indicate that the central and peripheral inhibitory effects of PCP and σ‐receptor ligands on [3H]‐NA uptake involves a receptor (σ1‐like) which is distinct from that (PCP2) recognized for the inhibition of [3 H]‐dopamine uptake by PCP.
...
1
2
3
...